226 related articles for article (PubMed ID: 31771255)
21. Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Int J Pharm; 2017 Jun; 526(1-2):88-94. PubMed ID: 28392278
[TBL] [Abstract][Full Text] [Related]
22. Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.
Mishra J; Rades T; Löbmann K; Grohganz H
Pharmaceutics; 2018 Apr; 10(2):. PubMed ID: 29649124
[TBL] [Abstract][Full Text] [Related]
23. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin.
Löbmann K; Laitinen R; Grohganz H; Strachan C; Rades T; Gordon KC
Int J Pharm; 2013 Aug; 453(1):80-7. PubMed ID: 22613066
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
[TBL] [Abstract][Full Text] [Related]
25. Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.
Jensen KT; Löbmann K; Rades T; Grohganz H
Pharmaceutics; 2014 Jul; 6(3):416-35. PubMed ID: 25025400
[TBL] [Abstract][Full Text] [Related]
26. A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation.
Ainurofiq A; Mauludin R; Mudhakir D; Soewandhi SN
Pharmaceutics; 2018 Jul; 10(3):. PubMed ID: 29986403
[TBL] [Abstract][Full Text] [Related]
27. Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Knapik-Kowalczuk J; Kramarczyk D; Jurkiewicz K; Chmiel K; Paluch M
Mol Pharm; 2021 Sep; 18(9):3588-3600. PubMed ID: 34420300
[TBL] [Abstract][Full Text] [Related]
28. Formulation of co-amorphous systems from naproxen and naproxen sodium and in situ monitoring of physicochemical state changes during dissolution testing by Raman spectroscopy.
Ueda H; Peter Bøtker J; Edinger M; Löbmann K; Grohganz H; Müllertz A; Rades T; Østergaard J
Int J Pharm; 2020 Sep; 587():119662. PubMed ID: 32682958
[TBL] [Abstract][Full Text] [Related]
29. Co-amorphous systems using epigallocatechin-3-gallate as a co-former: Stability, in vitro dissolution, in vivo bioavailability and underlying molecular mechanisms.
Chen J; Li H; Li X; Yuan D; Cheng H; Ke Y; Cheng J; Wang Z; Chen J; Li J
Eur J Pharm Biopharm; 2022 Sep; 178():82-93. PubMed ID: 35932965
[TBL] [Abstract][Full Text] [Related]
30. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
31. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
32. Exploring the physical stability of three nimesulide-indomethacin co-amorphous systems from the perspective of molecular aggregates.
Wang M; Liu S; Jia L; Zhang J; Du S; Gong J
Eur J Pharm Sci; 2020 Apr; 147():105294. PubMed ID: 32147483
[TBL] [Abstract][Full Text] [Related]
33. Effects of polymer addition on the non-strongly interacting binary co-amorphous system carvedilol-tryptophan.
Wang Y; Grohganz H; Rades T
Int J Pharm; 2022 Apr; 617():121625. PubMed ID: 35259442
[TBL] [Abstract][Full Text] [Related]
34. Vitrification and New Phases in the Water:Pyrimidine Binary Eutectic System.
Patyk-Kaźmierczak E; Podsiadło M; Szafrański M; Katrusiak A
J Phys Chem B; 2019 Aug; 123(33):7190-7196. PubMed ID: 31361487
[TBL] [Abstract][Full Text] [Related]
35. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
36. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.
Beyer A; Radi L; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Jul; 104():72-81. PubMed ID: 27130786
[TBL] [Abstract][Full Text] [Related]
37. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
38. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
39. Molecular structure and impact of amorphization strategies on intrinsic dissolution of spray dried indomethacin.
Li Y; Rantanen J; Yang M; Bohr A
Eur J Pharm Sci; 2019 Mar; 129():1-9. PubMed ID: 30553059
[TBL] [Abstract][Full Text] [Related]
40. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Int J Pharm; 2018 Jun; 544(1):172-180. PubMed ID: 29669257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
